A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2023-02-21
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate amount of mirikizumab (test) that gets into the
blood stream and how long it takes the body to get rid of it, when given via autoinjector
compared to mirikizumab (reference) solution given via autoinjector. The information about
any adverse effects experienced will be collected and the tolerability of mirikizumab will
also be evaluated.
Screening is required within 35 days prior to enrolment. For each participant, the total
duration of the clinical trial will be about 17 weeks including screening.